Israel-based pharmaceutical technology company Innocan Pharma Corporation has announced that its patent for the liposomal delivery platform LPT-CBD has been allowed in Japan and will be officially granted following the completion of administrative process.

The patent covers a prolonged-release liposome-based formulation that encapsulates cannabinoids, enabling the sustained release of synthetic CBD into the bloodstream.

It marks another significant step in Innocan’s global intellectual property expansion, joining its granted patent in India and forming part of a broader international patent family currently under review in multiple jurisdictions.

Given that Japan represents the third-largest pharmaceutical market in the world, valued at around USD 102 billion, this achievement represents an important milestone for Innocan in advancing LPT-CBD as a leading non-opioid solution for chronic pain management.

Iris Bincovich, Chief Executive Officer of Innocan Pharma, commented, "We are thrilled to receive this patent allowance for our proprietary technology. This allowance marks our second patent to be granted for LPT-CBD, following the one granted in India, further strengthening our innovation and global IP position. We look forward to a series of additional patent approvals worldwide."

Developed jointly in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem, LPT-CBD allows for prolonged exposure and maximises the bioavailability and therapeutic effects of CBD. Preclinical studies have shown that LPT-CBD provides prolonged pharmacokinetics and pain-relief effects lasting up to four weeks.

Following a successful pre-IND meeting, the US Food and Drug Administration (FDA) provided positive feedback to advance the development of LPT-CBD as a non-opioid alternative for chronic pain management.